The Medicines Company Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (14)

Latest Posts

About This Stock More About This Stock
4 Biotech Stocks To Watch In The New Year
Article By: Zacks Investment Research
Sunday, January 7, 2018 5:23 PM EDT
Biotech companies are continuously working on bringing innovative new treatments to market, and there could be significant catalysts in the coming quarters in the form of important product approvals as well as major data read-outs.
In this article: EBS, GSK, MDCO, XOMA, EXEL, NVS, MLNT
Read
Cholesterol Stocks Clobbered: Good Clinical Results But High Expectations
Article By: Rod Raynovich
Friday, March 17, 2017 10:17 AM EDT
Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of expectations and clobbered four stocks: AMGN, ESPR, MDCO and REGN.
In this article: AMGN, REGN, MDCO, ESPR Also: IBB, XBI, XLV
Read
Biotech Stocks Soar On Election Results, Gilead HBV Drug Approved
Article By: Arpita Dutt
Wednesday, November 16, 2016 3:30 PM EDT
The biotech sector responded favorably to Trump’s victory on hopes that there will be fewer drug pricing headwinds considering Trump was not as vocal as Hillary Clinton about rising drug prices and excessive price hikes.
In this article: ALNY, REGN, AMGN, GILD, MDCO, VRTX, ABBV
Read
On The Fly: After Hours Movers - 11/8
Article By: The Fly
Tuesday, November 8, 2016 2:44 AM EDT
ACADIA is up 9.6% after it said it expects data from its Phase 2 Alzheimer's psychosis study by the year's end. Mylan is down 0.9% after Senate Judiciary Committee leaders called on the Federal Trade Commission to review Mylan's business practices.
In this article: NWSA, FN, MAR, ACAD, FNSR, MDCO, MYL, PCLN
Read
Jefferies Sees 'Attractive Buying Opportunities' In Biotech
Article By: The Fly
Tuesday, October 18, 2016 10:16 AM EDT
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment.
In this article: IMMU, ALKS, CELG, GILD, MDCO, VRTX, CEMP, ALDR, RARE
Read

PARTNER HEADLINES

Latest Tweets for $MDCO

No tweets yet!